Interestingly, EV‐Apo (50−100 μg/mL) treatment significantly promoted the migration and invasion of breast cancer 4T1 cells in the presence of Raw264.7 macrophages, whereas EV‐alive exhibited minimal effects on that (Figure 1f). Here, AOPEP is linked to breast carcinoma.